-
Product Insights
Menkes Disease (Kinky Hair Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Menkes Disease (Kinky Hair Disease) - Drugs In Development, 2023’, provides an overview of the Menkes Disease (Kinky Hair Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Menkes Disease (Kinky Hair Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Inherited Neurodegenerative Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Inherited Neurodegenerative Diseases - Drugs In Development, 2023’, provides an overview of the Inherited Neurodegenerative Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inherited Neurodegenerative Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CUTX-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CUTX-101 Drug Details CUTX-101 (Copper histidinate) is under development for the treatment of Menkes...